Phase II Avastin Trial for Stage IIIB/IV NSCLC

This phase II clinical trial will address the issues of bevacizumab treatment duration and
treatment safety as first-line therapy for patients with non-squamous NSCLC. Following
disease progression or treatment failure, the potential benefit of continued bevacizumab
therapy will be tested by randomizing patients to two treatment arms, including second-line
chemotherapy with or without further bevacizumab. It is hypothesized that continuation of
bevacizumab with pemetrexed as second-line treatment following progression will result in
improved clinical outcomes for patients with NSCLC.